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bjectives The aim of our study was to evaluate the temporal trends in outcomes following percu-
aneous coronary intervention in lesions with angiographically visible thrombus and to assess the
mpact of drug-eluting stents (DES) on long-term outcomes.
ackground Percutaneous coronary intervention in the presence of angiographically visible throm-
us is associated with worse clinical outcomes. Whether recent advances in devices and adjunctive
harmacotherapy have made any signiﬁcant impact on clinical outcomes is unknown. Moreover,
oncerns have been raised about the safety of DES in thrombotic lesions.
ethods We conducted a retrospective analysis of 6,227 consecutive patients who had angio-
raphically visible thrombus. Patients were grouped into 3 eras depending on the dominant inter-
entional strategy of that time: early stent era (1990 to 1996), bare-metal stent era (1997 to 2003),
nd DES era (2003 to 2006).
esults Procedural success rates, although much improved, have remained unchanged in the last 2
ohorts (43%, 85%, 86%; p  0.001). Adjusted in-hospital mortality (4.7%, 3.0%, 3.6%; p  0.001),
nd major adverse cardiovascular events (7.8%, 5.0%, 5.3%; p  0.001) decreased modestly. During
ong-term follow-up, mortality and the combined end point of death or myocardial infarction were
imilar in the 3 cohorts; but the combined end point of death, myocardial infarction, or target lesion
evascularization (p  0.001) was lower in the 2 most recent eras.
onclusions There has been a marked improvement in procedural success accompanied by a re-
uction in in-hospital mortality and major adverse cardiac event rates. Importantly, the introduction
f DES has not been associated with a greater risk of death or myocardial infarction among patients
ith angiographically visible thrombus. (J Am Coll Cardiol Intv 2010;3:937–46) © 2010 by the
merican College of Cardiology Foundation
rom the *Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic College of Medicine and Mayo
oundation, Rochester, Minnesota; and the †Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine
nd Mayo Foundation, Rochester, Minnesota.anuscript received April 11, 2010; revised manuscript received June 11, 2010, accepted June 15, 2010.
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938he utilization of percutaneous coronary intervention (PCI)
as steadily increased over time due to greater operator
xperience, advances in device technology, and improved
djunctive pharmacotherapy. Percutaneous coronary inter-
ention is now performed for a broad spectrum of indica-
ions ranging from stable disease to ST-segment elevation
yocardial infarction (STEMI). However, there remain
pecific lesion subsets that are challenging and are associated
ith adverse outcomes. One such group of patients com-
rises those with intracoronary thrombus, which is typically
resent during acute coronary syndromes (ACS) (1,2). The
urden of thrombus is greatest in patients with STEMI in
hom it is usually occlusive, whereas non-STEMI is gen-
rally associated with nonocclusive thrombi (3,4).
See page 947
Important advances over the
past 15 years with respect to
performing PCI in thrombus-
rich lesions include: 1) the intro-
duction of coronary stents; 2)
the use of potent antiplatelet and
antithrombin drugs, and, more
recently; 3) thrombectomy and
distal protection devices. Con-
versely, there have been concerns
raised regarding the increased
potential for early and late stent
thrombosis with drug-eluting
stents (DES) in ACS (5–7), be-
cause the thrombus may act as a
nidus for stent thrombosis and
alter arterial wall drug delivery
and retention (8). Most pub-
lished studies exploring out-
comes with PCI in the presence
f visible thrombus have pre-dated these issues and do not
eflect contemporary practice. We hypothesized that out-
omes following PCI in the presence of thrombus have
mproved over time and that this has not been adversely
nfluenced by the introduction of DES. Thus, the aim of our
tudy was to evaluate the temporal trends, including the
mpact of DES, on in-hospital and long-term outcomes
ollowing PCI in patients with coronary lesions with angio-
raphically visible thrombus.
ethods
tudy population. The study included patients from January
990 to August 2006. Inclusion criterion was the presence
f thrombus on the diagnostic angiogram. The earliest
ualifying PCI per patient was considered the index event.
bbreviations
nd Acronyms
CS  acute coronary
yndrome
MS  bare-metal stent(s)
ABG  coronary artery
ypass graft
ES  drug-eluting stent(s)
ACE  major adverse
ardiac events
I  myocardial infarction
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
LR  target lesion
evascularizationatients with saphenous vein graft intervention were ex- eluded. We identified 6,227 patients who met these criteria.
he patients were divided into 3 groups according to the
ime of their intervention: 1) early stent era consisted of
atients from a time period when stents were predominantly
sed as a bailout strategy (January 1990 through December
996); 2) bare-metal stent (BMS) era included patients
rom a time period during which routine stenting with BMS
as the preferred strategy in conjunction with dual oral
ntiplatelet therapy (January 1997 through March 2003);
nd 3) DES era consisted of patients whose PCI reflects
ontemporary practice, including treatment with DES
April 2003 through August 2006). The Institutional Re-
iew Board at Mayo Clinic approved this study. In accor-
ance with a State of Minnesota statute, patients who did
ot grant authorization for medical records research were
lso excluded from the analysis (n  441). During the same
ime periods, we identified 2,710, 3,812, and 2,482 patients,
espectively, who presented with ACS, but without angio-
raphic evidence of thrombus who served as a control
opulation with respect to evaluating outcomes.
eﬁnitions used. Thrombus was defined prior to PCI by
isual estimation as an intraluminal filling defect with
ontrast on 3 sides or an area of contrast staining noted
ithin the stenosis and not having the angiographic char-
cteristics of dissection. The number of diseased coronary
rteries was defined by visual estimation as at least 1
oronary artery with 70% stenosis and 50% stenosis in the
thers. Patients with 50% stenosis in the left main
oronary artery were considered to have 2-vessel disease if
here was right dominance and 3-vessel disease if there was
eft dominance. Major adverse cardiovascular events
MACE) were defined as 1 or more of the following
ccurring during the index hospitalization: 1) death;
) Q-wave myocardial infarction; 3) urgent or emergent
oronary artery bypass graft (CABG); and 4) cerebrovascu-
ar accident defined as transient ischemic attack or stroke.
yocardial infarction (MI) was diagnosed in the presence
f 2 of the following 3 criteria: 1) typical chest pain for at
east 20 min; 2) elevation of creatine kinase (or the myo-
ardial band fraction) 2 times normal; and 3) a new
-wave on electrocardiogram. Acute coronary syndrome
as defined as unstable angina or a clinical diagnosis of MI
ithin the preceding 7 days. Data for bleeding complica-
ions were not collected systematically until 1994. Primary
CI was defined as PCI performed within 24 h of a MI
ithout preceding administration of thrombolytic. In-
ospital deaths included all deaths during the index hospital
dmission. Technical success was defined as a reduction of
esidual luminal diameter stenosis to no more than 20% in
he culprit vessel. Procedural success was defined as a
eduction of residual luminal diameter stenosis to no more
han 20% without in-hospital death, Q-wave MI, or need
or emergency CABG. For comparison with the early stent
ra, we also provide data for procedural success defined as a
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939eduction of residual luminal diameter stenosis to 50%
ithout in-hospital death, Q-wave MI, or need for emer-
ency CABG. Long-term outcomes studied included all-
ause mortality; death or any MI; and death, MI, or target
esion revascularization (TLR). Target lesion revasculariza-
ion was defined as any attempted percutaneous or surgical
evascularization of the target lesion after the initial
rocedure.
tatistical analysis. Data are presented as the mean SD or
s a frequency (percentage). Kaplan-Meier methods were
sed to estimate survival curves. Survival was analyzed in all
atients, with follow-up starting at the intervention. Tests
or trends across time groups were made using linear
ontrasts of means in a 1-way analysis of variance model for
umerical data (with transformations of skewed variables),
he Cochran-Armitage trend test for categorical data, and
y forcing a linear group effect in Cox proportional hazards
odels for time-to-event data. A multiple logistic regres-
ion model was created to estimate the partial association of
tents, glycoprotein IIb/IIIa inhibitors, and other devices
ith procedural success. The odds ratios were adjusted for
ge, MI within 24 h of PCI, any history of MI, pre-
rocedural shock, congestive heart failure on presentation,
Table 1. Baseline Clinical Characteristics
Variable
Overall
(N  6,227)
Early S
(n 
Age, yrs 64.5 12.6 64.3
Male sex 4,386 (70%) 1,63
Mayo Clinic risk score* 8.4 3.0 8.2
Diabetes mellitus 1,210 (20%) 45
Hypertension 3,460 (58%) 1,16
Hyperlipidemia 3,168 (60%) 89
Smoking status
Never 2,160 (35%) 84
Former 2,339 (38%) 90
Current 1,641 (27%) 58
Body mass index, kg/m2 29.0 5.4 28.4
Acute coronary syndrome 5,845 (94%) 2,19
Most recent myocardial infarction
24 h 2,759 (45%) 75
1–7 days 1,537 (25%) 60
7 days 717 (12%) 41
Never 1,184 (19%) 56
Pre-procedural shock* 561 (10%) 14
Prior PCI 795 (13%) 31
Prior CABG 391 (6%) 16
Peripheral vascular disease* 363 (7%) 11
CVA/TIA* 437 (9%) 9
Moderate/severe renal disease* 147 (3%) 4
Prophylactic IABP* 232 (5%) 4
Values presented as n(%) ormean SDunless otherwise indicated. The p values are for trend over time
BMS  bare-metal stent(s); CABG  coronary artery bypass grafting; CVA  cerebrovascular aintervention; TIA transient ischemic attack.ypertension, smoking history, peripheral vascular disease,
erebrovascular accident/transient ischemic attack, moder-
te/severe renal disease, chronic obstructive pulmonary dis-
ase, tumor, prophylactic intra-aortic balloon pump, ejec-
ion fraction 40%, baseline medication use, multivessel
isease, and moderate/severe angulation of lesion, which
ere selected on the basis of unadjusted statistical signifi-
ance. Adjusted rates of in-hospital events were calculated
s follows. A logistic regression model for the end point was
onstructed with the time era groups, Mayo Clinic risk
core, and C-type lesion as covariates. From that model, the
xpected event rate was calculated for the 3 groups if each
ad had the early stent group population. The resulting
stimate predicted probabilities were then averaged over the
ypothetical populations to get an expected group event
ate. A similar method was used to get adjusted follow-up
vent curves. In this case, however, the time era groups were
odeled with separate baseline hazards, whereas covariates
ere modeled according to the proportional hazards as-
umption. The p values for the comparison of time era
roups, however, were based on a model that assumed
roportional hazards. SAS versions 9.1.3 and 9.2 (SAS
nstitute, Cary, North Carolina) were used for all analyses.
ra
)
BMS Era
(n  2,367)
DES Era
(n  1,512) p Value
64.8 12.8 64.3 13.4 0.16
) 1,687 (71%) 1,064 (70%) 0.52
8.4 3.1 8.5 2.9 0.032
) 486 (21%) 274 (18%) 0.66
) 1,341 (60%) 950 (68%) 0.001
) 1,345 (66%) 924 (70%) 0.001
0.14
) 789 (34%) 528 (36%)
) 921 (39%) 509 (35%)
) 628 (27%) 428 (29%)
29.3 5.4 29.4 5.8 0.43
) 2,213 (93%) 1,436 (95%) 0.092
) 1,077 (46%) 923 (61%) 0.001
) 602 (26%) 329 (22%)
) 218 (9%) 85 (6%)
) 459 (19%) 164 (11%)
260 (11%) 152 (10%) 0.030
) 265 (11%) 215 (14%) 0.74
136 (6%) 87 (6%) 0.056
) 147 (6%) 98 (7%) 0.001
214 (9%) 128 (9%) 0.93
52 (2%) 47 (3%) 0.18
109 (5%) 83 (5%) 0.016
or this variable is only available in the 1,121 PCIs from January 1, 1994 onward in the early stent era.
t; DES  drug-eluting stent(s); IABP  intra-aortic balloon pump; PCI  percutaneous coronarytent E
2,348
 11.9
5 (70%
 3.0
0 (19%
9 (50%
9 (46%
3 (36%
9 (39%
5 (25%
 5.0
6 (94%
9 (32%
6 (26%
4 (18%
1 (24%
9 (8%)
5 (13%
8 (7%)
8 (10%
5 (8%)
8 (4%)
0 (4%)
. *Data f
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940esults
aseline characteristics. The clinical characteristics of pa-
ients in the 3 eras are summarized in Table 1. The age,
roportion of each sex, and frequency of diabetics were
imilar over the time periods, but the prevalence of hyper-
ension and hyperlipidemia has increased. As expected,
early all patients presented with an ACS, but the propor-
ion diagnosed as an acute MI within 24 h of PCI increased
ver time. This is likely due to the use of more sensitive
iomarkers of myonecrosis, and the revised definition of MI
ver the study period. The use of dual antiplatelet therapy
Table 2. Angiographic and Procedural Characteristics
Variable
Overall
(N  6,227)
Number of vessels diseased
Single 1,913 (32%)
Double 2,247 (37%)
Triple 1,834 (31%)
Type C lesion 2,216 (49%)
Pre-procedural TIMI ﬂow grade 0 or 1* 2,336 (52%)
Primary PCI* 2,115 (42%)
Vessel treated
Left anterior descending 2,506 (40%)
Right coronary artery 2,753 (44%)
Circumﬂex artery 1,470 (24%)
Left main artery 63 (1%)
Total number of stents placed 0.9 1.0
DES use 1,019 (16%)
GP IIb/IIIa inhibitor use 3,166 (51%)
AngioJet use 153 (2%)
Aspiration catheter 54 (0.9%)
Distal protection device 40 (0.7%)
TIMI ﬂow grade 3 post PCI* 5,063 (91%)
Technical success 4,511 (72%)
Procedural success (deﬁned as 20% residual stenosis) 4,322 (69%)
Procedural success (deﬁned as 50% residual stenosis) 5,500 (88%)
Bleeding complications
Femoral artery bleeding
Groin hematoma
Bleeding requiring blood transfusion
Central nervous bleeding
Gastrointestinal tract bleeding
Retroperitoneal bleeding
Medications at discharge
Aspirin 5,647 (91%)
Ticlid 617 (10%)
Clopidogrel 3,119 (50%)
Beta-blocker 4,751 (76%)
ACE inhibitor 2,598 (43%)
Lipid-lowering therapy 2,811 (46%)
Values are presented as n(%) or mean SD unless otherwise indicated. The p values are for trend o
stent era.ACE angiotensin converting enzyme; GP glycoprotein; TIMI Thrombolysis In Myocardial Infarctionnd drugs for secondary prevention was significantly higher
n the recent cohorts.
ngiographic and procedural characteristics. Table 2
ummarizes the angiographic and procedural characteris-
ics of the groups. There was no difference in the
revalence of multivessel disease or the distribution of the
arget vessel treated among the groups. However, the
omplexity of the treated lesions has increased over time,
s manifest by a higher frequency of type C lesions and
re-procedural Thrombolysis In Myocardial Infarction
TIMI) flow grade 0 or 1. The use of glycoprotein
Ib/IIIa inhibitors, stents, mechanical thrombectomy de-
Early Stent Era
(n  2,348)
BMS Era
(n  2,367)
DES Era
(n  1,512) p Value
0.26
707 (31%) 716 (32%) 490 (34%)
869 (38%) 852 (38%) 526 (36%)
709 (31%) 697 (31%) 428 (30%)
496 (31%) 876 (50%) 844 (70%) 0.001
768 (50%) 864 (51%) 704 (56%) 0.001
375 (33%) 958 (40%) 782 (52%) 0.001
935 (40%) 992 (42%) 579 (38%) 0.51
1,022 (44%) 1,044 (44%) 687 (45%) 0.26
577 (25%) 536 (23%) 357 (24%) 0.38
17 (1%) 28 (1%) 18 (1%) 0.12
0.3 0.7 1.4 1.0 1.3 0.8 0.001
0 (0%) 0 (0%) 1,019 (67%) 0.001
189 (8%) 1,754 (74%) 1,223 (81%) 0.001
0 (0%) 78 (3%) 75 (5%) 0.001
0 (0%) 0 (0%) 54 (0.9%) 0.001
0 (0%) 5 (0.2%) 35 (2.4%) 0.001
1,660 (91%) 2,073 (91%) 1,330 (93%) 0.025
1,044 (44%) 2,099 (89%) 1,368 (90%) 0.001
999 (43%) 2,019 (85%) 1,304 (86%) 0.001
1,990 (85%) 2,151 (91%) 1,359 (90%) 0.001
31 (1.3%) 9 (0.6%) 0.011
100 (4.2%) 51 (3.4%) 0.001
238 (10.1%) 97 (6.4%) 0.005
0 (0.0%) 0 (0.0%)
30 (1.3%) 27 (1.8%) 0.82
8 (0.3%) 7 (0.5%) 0.18
2,046 (87%) 2,189 (92%) 1,412 (93%) 0.001
298 (13%) 316 (14%) 3 (0%) 0.001
1 (0%) 1,725 (73%) 1,393 (92%) 0.001
1,485 (63%) 1,914 (81%) 1,352 (89%) 0.001
426 (19%) 1,110 (48%) 1,062 (72%) 0.001
427 (19%) 1,515 (65%) 869 (59%) 0.001
e. *Data for this variable is only available in the 1,121 PCIs from January 1, 1994 onward in the earlyver tim; other abbreviations as in Table 1.
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941ices, and distal protection devices increased over time in
uccessive cohorts accompanied by higher technical and
rocedural success rates (Fig. 1, Table 2). Procedural
uccess rates for primary PCI were 49%, 81%, and 83%,
espectively, for the 3 eras (p  0.001) whereas those for
he nonprimary PCI patients were 64%, 88%, and 89%,
espectively (p  0.001).
By multivariable analysis, the use of stents (odds ratio:
4.7 [interquartile range (IQR) 11.4 to 18.9]; p  0.001)
as the only independent predictor of procedural success in
he entire cohort (Table 3) as well as the subgroup of
rimary PCI patients (odds ratio: 14.9 [IQR 10.5 to 21.1];
 0.001).
utcomes. In-hospital clinical outcomes for patients with and
ithout angiographic evidence of thrombus, adjusted for Mayo
linic risk score (9), and the presence of type C lesions are
hown in Figure 2. The rates of in-hospital mortality, need for
mergency CABG, and the combined end point of MACE
ecreased over time (Figs. 1 and 2). Similar trends were seen in
he primary PCI subgroup, though their event rates were
igher (Fig. 2).
Femoral access site bleeding complications and the
eed for blood transfusion have also decreased, but the
ates of gastrointestinal tract and retroperitoneal bleeding
emain unchanged.
The median duration of follow-up was 157 (interquartile
Figure 1. Temporal Trends in the Use of Devices, Glycoprotein IIb/IIIa Inhi
Temporal trends in the use of stents, thrombectomy devices, and glycoprotein
rates over the duration of the study. Procedural success was deﬁned as a redu
tal death, Q-wave myocardial infarction, or need for emergency coronary arter
nary intervention.ange 134 to 179), 86 (IQR 64 to 106), and 23 (IQR 11 to 36)Table 3. Independent Predictors of Procedural Success
Variable OR 95% CI p Value
Stent use 14.7 11.4–18.9 0.001
Pre-procedural shock 0.38 0.28–0.52 0.001
Moderate to severe
angulation of culprit artery
0.55 0.44–0.68 0.001
Prophylactic IABP 0.39 0.26–0.59 0.001
Left ventricle ejection
fraction 40%
0.63 0.46–0.88 0.006
MI within 24 h 0.77 0.61–0.96 0.022
History of MI (7 days) 1.34 1.00–1.80 0.053
Chronic renal failure 0.60 0.34–1.05 0.074
Age (per decade) 0.92 0.84–1.01 0.075
Peripheral vascular disease 0.72 0.48–1.08 0.11
Multivessel disease 0.83 0.65–1.05 0.12
Baseline medication score* 1.09 0.97–1.22 0.17
Tumor/lymphoma/leukemia 0.83 0.61–1.15 0.27
Glycoprotein IIb/IIIa inhibitors 1.13 0.90–1.44 0.30
Hypertension 0.90 0.71–1.14 0.37
COPD 0.91 0.66–1.26 0.57
CVA/TIA 0.90 0.63–1.29 0.57
Congestive heart failure 0.92 0.67–1.26 0.61
Smoking 1.04 0.83–1.31 0.74
*Baseline medication use score is the number of the following medications being taken at
baseline: aspirin, beta-blocker, calcium channel blocker, and ACE inhibitor.
CI  confidence interval; COPD  chronic obstructive pulmonary disease; MI  myocardialbitors, Procedural Success, and MACE Rates
IIb/IIIa inhibitors as well as procedural success and major adverse cardiac event
ction of residual luminal diameter stenosis to no more than 20% without in-hospi-
y bypass graft. MACE  major adverse cardiac events; PCI  percutaneous coro-infarction; OR odds ratio; other abbreviations as in Tables 1 and 2.
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942onths, respectively, for the 3 groups. Sixty-four percent
f patients had follow-up available within 1 year of
reezing the data for analysis, and 92% had follow-up
vailable in the prior 2 years. The adjusted long-term
ortality and the combined end point of death or MI
ollowing discharge have remained unchanged in 3 eras
Figs. 3A and 3B). There has been a significant reduction
n the combined end point of death, MI, or TLR in the
tent eras (Fig. 3C). Patients with angiographic thrombus
ad significantly higher rates of death (p  0.001) and
eath/MI (p  0.001) than did patients without throm-
us, mostly due to differences in early event rates (Fig. 3).
ndependent predictors of death or MI during follow-up
n patients with thrombus are shown in Table 4. Other
ariables included in the multivariable model that were
ot predictive of the outcome were stent use, DES use,
ender, hypertension, hyperlipidemia, previous smoker,
I within 24 h of PCI, MI within 7 days, past history of
Figure 2. Adjusted In-Hospital Clinical Outcomes
Adjusted in-hospital clinical outcomes for all patients with angiographic throm
thrombus (middle), and acute coronary syndrome patients without angiograp
stent era for cases from 1994 to 1996. ACS  acute coronary syndrome; BMS 
stent(s); other abbreviations as in Figure 1.I, and primary PCI. piscussion
he major findings of the present study conducted among
,227 patients undergoing PCI for thrombotic coronary
esions over a period of 17 years are that: 1) increased use of
tents has been associated with a marked improvement in
echnical and overall procedural success though this has
eveled off in the most recent era; 2) this has been associated
ith a decrease in in-hospital mortality and MACE rates;
) the use of DES is not associated with an increased risk of
ong-term mortality or MI; and 4) there is an increasing use
f new thrombectomy devices in clinical practice.
rends in in-hospital outcomes and the impact of stents. Prior
ata from observational studies (2) and randomized trials
10) have clearly indicated that the presence of thrombus on
he angiogram is an independent predictor of major adverse
linical events due to an increased risk of abrupt closure,
istal embolization, and procedural failure (11–14). The
op), primary percutaneous coronary intervention cases with angiographic
idence of thrombus (bottom). Adjustment was only available in the early
-metal stent(s); CABG  coronary artery bypass graft; DES  drug-elutingbus (t
hic ev
bareresent study represents the largest cohort of patients with
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943ngiographic thrombus reported to date, inclusive of pa-
ients with MI of any severity, and provides data on
ontemporary practice. The data confirm that outcomes are
orse in this patient population compared with those
ithout angiographic thrombus. We report a marked im-
rovement in the rate of procedural success over time,
Figure 3. Kaplan-Meier Estimates for MACE Rates During Follow-Up
Kaplan-Meier estimates for (A) death; (B) death or myocardial infarction; (C) de
onward. Panels on left are for patients with angiographic thrombus and on th
of thrombus. These estimates are adjusted for age, sex, diabetes, hypertension
taneous coronary intervention, myocardial infarction within 1 to 7 days before
before percutaneous coronary intervention, before percutaneous coronary inte
vention, congestive heart failure, multivessel disease, ejection fraction 40%, i
emic attack, tumor/lymphoma/leukemia, chronic renal disease, chronic obstruc
channel blockers, thienopyridines, lipid-lowering agents, and angiotensin-conv
cases from 1994 to 1996. MI  myocardial infarction; TLR  target lesion revahough it has leveled off with the routine use of stents at tpproximately 85%. This compares to an overall procedural
uccess rate of 94% in our practice, as reported previously
15). It is encouraging to observe that in-hospital mortality
nd the composite end point of MACE have decreased over
ime (Figs. 1 and 2). The improvement in procedural
uccess and in-hospital outcomes have paralleled the adop-
yocardial infarction, or target lesion revascularization from discharge
t for patients with acute coronary syndrome without angiographic evidence
cholesterol, smoking history, myocardial infarction within 24 h before percu-
taneous coronary intervention, any history of myocardial infarction 7 days
on shock, peripheral vascular disease, primary percutaneous coronary inter-
ortic balloon pump use, history of cerebrovascular accident/transient isch-
ulmonary disease, and medication use (aspirin, beta-blockers, calcium
enzyme inhibitors. Adjustment was only available in the early stent era for
zation; other abbreviations as in Figures 1 and 2.ath, m
e righ
, high
percu
rventi
ntra-a
tive p
ertingion of stents (90%) as the standard of care in this patient
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944opulation, and a direct association is supported by the fact
hat stent use was the only independent predictor of
rocedural success.
Recent evidence suggests that bleeding and blood trans-
usions following PCI may be independent determinants of
dverse outcomes (16). Thus, it is reassuring that there has
een a decline in the frequency of femoral artery access site
leeding and the need for blood transfusions in patients
ith thrombotic lesions who receive the most aggressive
djunctive antiplatelet and anticoagulant therapy. The rea-
ons for the reduction in access site bleeding cannot be
etermined from the present study, but potential reasons
nclude smaller sheaths, shorter sheath dwell time, reduced
ntensity of intraprocedural anticoagulation, and the avoid-
nce of post-procedure heparin infusions (17). In contrast,
he rates of retroperitoneal and gastrointestinal tract bleed-
ng have not decreased. Both these major hemorrhagic
omplications are associated with an increased morbidity
nd mortality and efforts need to be continued to develop
trategies to decrease their occurrence. However, this rep-
esents a challenge as novel and more potent antithrombotic
gents developed for this patient population invariably
ppear to be associated with a greater risk of bleeding (18).
his highlights 1 rationale for developing mechanical ad-
unctive antithrombotic devices.
As is the case with other patients undergoing PCI
15,19), we demonstrate that in-hospital mortality, adjusted
or the increasing frequency of adverse clinical and angio-
raphic lesion characteristics, has decreased significantly
ver the 17-year period of the analysis in this high-risk
ohort. In contrast, long-term mortality has not decreased,
Table 4. Independent Predictors of Death or MI During Follow-Up
Variable HR 95% CI p Value
Age 1.03 1.03–1.04 0.001
Cardiogenic shock 1.61 1.38–1.88 0.001
Diabetes mellitus 1.39 1.24–1.56 0.001
Chronic renal failure 1.96 1.59–2.42 0.001
COPD 1.41 1.24–1.62 0.001
Congestive heart failure 1.18 1.10–1.26 0.001
Peripheral vascular disease 1.40 1.20–1.64 0.001
Current smoking 1.30 1.23–1.48 0.001
CVA/TIA 1.29 1.10–1.48 0.001
Ejection fraction 40% 1.28 1.11–1.48 0.001
Multivessel disease 1.24 1.10–1.40 0.001
Prior CABG 1.34 1.12–1.60 0.001
Prophylactic IABP use 1.68 1.38–2.04 0.001
Tumor/lymphoma/leukemia 1.39 1.21–1.58 0.001
Baseline use of calcium
channel blockers or ACE
inhibitors
1.16 1.04–1.29 0.008
HR hazard ratio, other abbreviations as in Tables 1 to 3.hich is consistent with randomized clinical trials of coro- aary stenting in ACS that have consistently demonstrated
hat stents, compared with balloon angioplasty, do not
educe long-term mortality (20,21). The trials did demon-
trate, as seen in the present observational study, that the
se of stents is associated with a reduction in ischemic
omplications related to PCI in thrombotic lesions and the
ubsequent need for revascularization. Similarly, the pre-
ominant benefit observed in clinical trials of glycoprotein
Ib/IIIa inhibitors as adjunctive therapy for PCI in ACS has
een to reduce periprocedural MI rather than mortality
22–24).
ES and long-term outcomes. Drug-eluting stents have
een a major advance in PCI and are superior to BMS with
egards to reducing restenosis and TLR (25–31). Our study
uggests that DES use reduces TLR in thrombotic lesions
n clinical practice. Recently, there have been growing
oncerns regarding the safety of DES use, particularly in the
resence of an angiographically visible thrombus, due to the
ncreased risk for late and very late stent thrombosis with
ssociated increased morbidity and mortality (6,7). Obser-
ational data also suggest that there is increased pre-
isposition to late stent thrombosis in patients with ACS,
erhaps due to the presence of an inflammatory and
hrombogenic milieu in the lesion (32). In this regard, data
rom our registry are reassuring, because the mortality and
he combined end point of death or MI in the DES era were
imilar to that observed in the BMS era. Taken together
ith the findings of prior randomized trials comparing
MS and DES in STEMI (33), and the recently published
ORIZONS AMI (Harmonizing Outcomes With Revas-
ularization and Stents in Acute Myocardial Infarction) trial
34), in which the use of the paclitaxel-eluting stent in
TEMI was not associated with a higher rate of stent
hrombosis or MACE when compared with the use of
MS; the body of evidence suggests that DES use is safe in
hrombotic lesions, though longer-term follow-up is re-
uired (34,35). Though the use, or type, of stent did not
redict adverse long-term outcomes, markers of atherosclerotic
urden and the presence of comorbid diseases (Table 4)
ndependently predicted the occurrence of death or MI during
ollow-up.
hrombectomy and distal protection devices. We speculate
hat the inability to improve survival in this patient popu-
ation may, in part, be due to the limitation of current PCI
echniques in preventing macro- and micro-embolization
nd the resulting microvascular dysfunction in patients with
hrombotic lesions (1). Distal embolization is a universal
henomenon during PCI for MI, occurring pre-dominantly
t the time of first balloon inflation and stent deployment
36). Moreover, thrombus burden is as an independent
redictor of adverse outcomes (5,37). Thus, there is a need
o develop novel strategies to remove thrombus during PCI
ith the goal of improving outcomes. In the presentnalysis, we observed a gradual increase in the use of
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945spiration and AngioJet thrombectomy catheters (Possis
edical, Minneapolis, Minnesota) as well as distal protec-
ion devices (Fig. 1). The mechanical thrombectomy devices
ere used in10% of cases, even in the most recent cohort,
nd, therefore, the number of cases are insufficient to assess
heir clinical impact. Based on current evidence, we recom-
end that aspiration thrombectomy is the preferred adjunc-
ive mechanical strategy of choice for the majority of
atients undergoing primary PCI (38).
tudy limitations. Although the data were collected pro-
pectively, this is a retrospective single-center analysis sub-
ect to the limitations of such analyses. However, the large
ample size and consistent definition of all variables from a
ingle-center registry is a major strength for analyzing
rends over time. Core angiographic laboratory analysis and
uantitative assessment of thrombus burden were not per-
ormed. Although independent core laboratory data would
ave been very helpful, it is not feasible in such a large study.
oreover, there are significant limitations of angiographic
ssessment of thrombus, which is less sensitive and specific
han angioscopy, though the latter technique is not used in
linical practice (39). The impact of this was reduced to
ome extent by the large sample size and the use of a single
onsistent definition of thrombus. We did not have data on
he loading dose and timing of clopidogrel administration,
nd, therefore, cannot explore the impact of thienopyridine
herapy on outcomes. However, in general, the loading dose
f clopidogrel is administered at the time of PCI in our
ractice. Bivalirudin was not used in these patients and
herefore we cannot comment on the impact of direct
hrombin inhibitors on large thrombus burden.
onclusions and Implications
hough there has been a marked improvement over the
arly stent era, procedural success rate in thrombotic lesions
as remained around 85% over the past decade. The routine
se of stents in contemporary practice has been associated
ith a reduction in in-hospital mortality and MACE rates
n those with thrombotic lesions. Importantly, the selective
se of DES in the presence of a coronary thrombus, as
erformed in contemporary practice, is not associated with
orse short- and long-term clinical outcomes. There re-
ains a need for continued effort to develop new tech-
iques, devices, and an optimal adjunctive pharmacotherapy
egimen to further improve the success rates as well as
linical outcomes in this high-risk subset.
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